# US Central Nervous System Biomarkers Market

> US Central Nervous System Biomarkers Market Research Report By Type Procedure (Safety, Efficacy, Validation Biomarker) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.35%
- **2024:** $ 1,823.3 Million
- **2025:** $ 1,975.55 Million
- **2035:** $ 4,405.24 Million
- **Key Players:** Roche (CH), AbbVie (US), Biogen (US), Eli Lilly (US), Novartis (CH), Amgen (US), Merck (DE), Pfizer (US), Johnson & Johnson (US)

**Report ID:** MRFR/HC/17780-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-central-nervous-system-biomarkers-market-19327

---

## Market Summary

## **US Central Nervous System Biomarkers Market Overview**

As per MRFR analysis, the US Central Nervous System Biomarkers Market Size was estimated at 1.32 (USD Billion) in 2023. The US Central Nervous System Biomarkers Market Industry is expected to grow from 1.5(USD Billion) in 2024 to 4 (USD Billion) by 2035. The US Central Nervous System Biomarkers Market CAGR (growth rate) is expected to be around 9.326% during the forecast period (2025 - 2035).

### **Key US Central Nervous System Biomarkers Market Trends Highlighted**

The US Central Nervous System Biomarkers Market is experiencing several notable trends driven by advancements in technology and an increased understanding of neurological disorders. A key market driver is the aging population, as the number of individuals affected by conditions such as Alzheimer's and Parkinson's continues to rise. This demographic shift is pushing for more effective diagnostic and therapeutic solutions, leading to greater investments in biomarkers research and development.

Additionally, there is a growing emphasis on personalized medicine, where biomarkers play a crucial role in tailoring treatment plans to individual patients, enhancing treatment efficacy and patient outcomes. Opportunities in the US market include the integration of artificial intelligence and machine learning in biomarker discovery and analysis. These technologies can streamline research processes and lead to the identification of new biomarkers at a faster pace.

The collaboration between academic institutions and biotech firms is also paving the way for innovative approaches to biomarker development, creating a synergy that can accelerate advancements in central nervous system (CNS) research. Recent times have seen a significant trend towards regulatory advancements and support for biomarker validation within the US. The FDA has shown a commitment to establishing clear pathways for the approval of CNS biomarkers, thereby fostering innovation and ensuring safety in diagnostics.

Moreover, the focus on multi-modal biomarker approaches, which combine genomic, proteomic, and neuroimaging data, is gaining traction, providing a more comprehensive understanding of neurological diseases. Overall, these trends reflect a dynamic and evolving landscape that is reshaping the US Central Nervous System Biomarkers Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Central Nervous System Biomarkers Market Drivers**

### **Rising Prevalence of Neurological Disorders**

The increasing prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis is driving the growth of the US Central Nervous System Biomarkers Market Industry. According to the Alzheimer's Association, approximately 6.2 million Americans age 65 and older are living with Alzheimer's disease in 2021, a number that is projected to rise to nearly 14 million by 2060.

This alarming statistic emphasizes the significant need for effective diagnostic tools, including biomarkers, to manage these conditions. As organizations such as the National Institute of Neurological Disorders and Stroke allocate substantial funding towards Research and Development initiatives aimed at advancing biomarker discovery and validation, the market for central nervous system biomarkers is expected to experience considerable growth in the coming decade.

Improved diagnostics not only aid in patient management but also enhance the development of targeted therapies, further fueling market demand. Additionally, the growing awareness of mental health issues in the US, highlighted by initiatives from the Substance Abuse and Mental Health Services Administration, underscores the need for reliable biomarkers to better understand and treat these conditions.

### **Technological Advancements in Biomarker Discovery**

Technological advancements in biomarker discovery and analysis techniques are significantly propelling the US Central Nervous System Biomarkers Market Industry. Innovations in genomics, proteomics, and metabolomics have facilitated the identification of novel biomarkers. For instance, the expansion of next-generation sequencing technology has made it easier to detect genetic markers associated with neurological diseases.

The National Institutes of Health has been actively funding projects that utilize advanced technologies to expedite biomarker identification. As these technologies evolve, they not only enhance the accuracy and speed of biomarker discovery but also lower the costs associated with research. This trend is leading to a broader adoption of biomarkers in clinical practice, ultimately boosting the market.

### **Increased Investment in Neurodegenerative Disease Research**

The US government and private sectors are significantly increasing their investment in Research and Development initiatives aimed at understanding neurodegenerative diseases, which is a major driver for the US Central Nervous System Biomarkers Market Industry. The National Institutes of Health reported that funding for Alzheimer's disease research has increased by approximately 200% over the past decade, reaching over $3 billion in recent years.

This substantial financial commitment reflects the urgency of addressing the growing burden of neurodegenerative diseases. As a result, researchers are actively working on identifying and validating new biomarkers that can lead to better diagnostics and treatment options, rendering the market growth favorable in the coming years.

## **US Central Nervous System Biomarkers Market Segment Insights**

### **Central Nervous System Biomarkers Market Type Procedure Insights**

The US Central Nervous System Biomarkers Market focuses extensively on the Type Procedure segment, which encompasses various critical elements for understanding neurological conditions. This segment plays a significant role in advancing knowledge and treatment options in the field of neurology, which is essential considering the increasing prevalence of neurological disorders within the population.

As researchers and healthcare providers increasingly rely on these biomarkers, new advancements in diagnostics and therapeutic approaches are anticipated, reinforcing the importance of this segment in the broader context of the US Central Nervous System Biomarkers Market. Additionally, the implications of robust US government-sponsored initiatives and funding towards neuroscience research enhance the market potential for these Type Procedure biomarkers. This focus on expanding the understanding of biomarker applications brings opportunities to innovate and improve patient outcomes while navigating challenges such as regulatory hurdles and the need for extensive clinical trials.

The ongoing investment in Research and Development within the US further supports these dynamics, ultimately leading to enhanced population health management strategies that address the growing demands for effective neurological care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Central Nervous System Biomarkers Market Key Players and Competitive Insights**

The US Central Nervous System Biomarkers Market is characterized by a dynamic competitive landscape. Various players are engaged in developing innovative biomarkers to enhance diagnostics and treatment options for neurodegenerative diseases, psychiatric disorders, and other CNS-related conditions. These biomarkers play a crucial role in the early detection and monitoring of diseases, thereby improving patient outcomes and facilitating personalized medicine approaches. Companies operating in this market are leveraging advanced technologies and pursuing strategic collaborations to enhance their product offerings and expand their market presence.

As the demand for efficient diagnostic tools continues to rise, the competitive dynamics are fueled by ongoing research initiatives and increased investment in the CNS biomarker domain, highlighting the significant opportunities and challenges that lie ahead for market participants.

Teva Pharmaceutical excipients Industries has established a noteworthy position in the US Central Nervous System Biomarkers Market, primarily focusing on the development of generic and specialty medications tailored to treat CNS disorders. The company’s strengths lie in its extensive research capabilities, strong portfolio of CNS therapeutic options, and a dedicated commitment to addressing unmet medical needs in areas such as epilepsy, migraine, and pain management. Teva’s position is further reinforced by its robust distribution network and established relationships with healthcare providers.

The organization’s ability to innovate while maintaining cost-effective solutions ensures its competitive edge in the market, making it a recognized name among healthcare professionals and stakeholders involved in CNS biomarker research and application.

AstraZeneca has a significant footprint in the US Central Nervous System Biomarkers Market, with a focus on developing effective treatments and diagnostics for diseases such as Alzheimer’s and schizophrenia. The company’s strengths lie in its cutting-edge research on biomarkers that facilitate the early diagnosis and treatment efficacy of CNS disorders. AstraZeneca's portfolio includes a variety of biochemical agents and therapeutic solutions that demonstrate its commitment to improving patient outcomes. The company actively pursues mergers and acquisitions to bolster its research capabilities and expand its product offerings in the CNS sector, enhancing its competitive positioning.

By integrating novel biomarkers into its clinical research, AstraZeneca aims to enhance the precision of drug development and ultimately deliver better therapeutic options for patients suffering from CNS disorders in the US market.

### **Key Companies in the US Central Nervous System Biomarkers Market Include**

### **US Central Nervous System Biomarkers Market Industry Developments**

In recent months, the US Central Nervous System Biomarkers Market has seen notable advancements and developments, particularly concerning key players like Teva Pharmaceutical Industries, AstraZeneca, and Eli Lilly. In September 2023, Teva announced a strategic partnership with a biotechnology firm to develop new neurological biomarkers which could enhance the diagnosis and management of neurological disorders.

Additionally, AstraZeneca's recent focus on neurodegenerative diseases has led to promising results in clinical trials for biomarkers that could potentially improve treatment outcomes. Furthermore, in October 2023, Eli Lilly reported positive progress with its Alzheimer’s disease biomarker, showing potential for earlier diagnosis, thus impacting market dynamics favorably.

In terms of mergers and acquisitions, in July 2023, Merck acquired a startup specialized in CNS biomarker technologies, a move expected to strengthen its research capabilities in neurodegenerative diseases. The valuation of companies within this market has been significant due to increased investments directed at Research and Development, driven by the rise in neurological disorders in the US. Over the past two years, there has been a growing emphasis on precision medicine within the CNS biomarkers landscape, marking an evolution in how neurological diseases are approached and managed in clinical settings.

## **US Central Nervous System Biomarkers Market Segmentation Insights**

### **Central Nervous System Biomarkers Market Type Procedure Outlook**

## Market Drivers

### Growing Demand for Early Diagnosis

The increasing emphasis on early diagnosis of neurological conditions is significantly impacting the central nervous-system-biomarkers market. Early detection is crucial for effective intervention and management of diseases such as Alzheimer's and Parkinson's, where timely treatment can slow disease progression. The market is witnessing a shift towards the development of biomarkers that can facilitate early diagnosis, with studies indicating that early intervention can improve patient outcomes by up to 40%. This growing demand for early diagnostic solutions is likely to drive innovation and investment in the central nervous-system-biomarkers market, as healthcare providers seek to implement strategies that enhance patient care.

### Advancements in Diagnostic Technologies

Technological innovations in diagnostic methodologies are significantly influencing the central nervous-system-biomarkers market. The integration of advanced imaging techniques, such as MRI and PET scans, alongside biomarker analysis, is enhancing the accuracy of neurological disorder diagnoses. For instance, the use of neuroimaging combined with biomarker profiling has shown to improve diagnostic precision by up to 30%. As these technologies evolve, they are likely to facilitate the identification of biomarkers that can predict disease progression and treatment response. Consequently, the central nervous-system-biomarkers market is poised for growth as healthcare systems increasingly adopt these sophisticated diagnostic tools to improve patient care and streamline clinical workflows.

### Increased Funding for Neuroscience Research

The surge in funding for neuroscience research is a crucial driver for the central nervous-system-biomarkers market. Government and private sector investments have been on the rise, with the National Institutes of Health (NIH) allocating over $3 billion annually for brain research initiatives. This financial support fosters innovation in biomarker discovery and validation, enabling researchers to explore new avenues for understanding complex neurological conditions. As funding continues to grow, the central nervous-system-biomarkers market is likely to expand, driven by the development of novel biomarkers that can lead to breakthroughs in treatment and management of neurological disorders.

### Rising Prevalence of Neurological Disorders

The increasing incidence of neurological disorders in the US is a primary driver for the central nervous-system-biomarkers market. Conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are becoming more prevalent, with estimates suggesting that by 2030, approximately 7.2 million individuals will be living with Alzheimer's alone. This surge in cases necessitates the development of effective diagnostic tools, thereby propelling the demand for biomarkers that can aid in early detection and monitoring of these diseases. The central nervous system biomarkers market is expected to witness substantial growth as healthcare providers seek innovative solutions to address the challenges posed by these disorders. This growth will ultimately enhance patient outcomes and reduce healthcare costs.

### Regulatory Support for Biomarker Development

Regulatory bodies in the US are increasingly supporting the development of biomarkers through streamlined approval processes and guidelines. The FDA has established programs aimed at expediting the review of biomarker-based diagnostics, which encourages innovation in the central nervous-system-biomarkers market. This regulatory support not only facilitates faster market entry for new biomarkers but also enhances collaboration between industry stakeholders and regulatory agencies. As a result, the central nervous-system-biomarkers market is expected to benefit from a more favorable environment for research and development, ultimately leading to the introduction of novel diagnostic tools that can improve patient management.

## Future Outlook

The [Central Nervous System Biomarkers Market](https://www.marketresearchfuture.com/reports/central-nervous-system-biomarkers-market-9140) is projected to grow at 8.35% CAGR from 2025 to 2035, driven by advancements in diagnostics, increasing prevalence of neurological disorders, and rising healthcare investments.

**New opportunities:**

- Development of personalized biomarker panels for targeted therapies. Integration of AI-driven analytics for enhanced diagnostic accuracy. Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)services for remote biomarker monitoring.

By 2035, the market is expected to achieve substantial growth, reflecting its critical role in healthcare.

## Segment Insights

### By Type: Safety Biomarker (Largest) vs. Efficacy Biomarker (Fastest-Growing)

In the US central nervous-system-biomarkers market, the distribution of market share reveals that Safety Biomarkers hold the largest share due to their critical role in ensuring patient safety during clinical trials. Efficacy Biomarkers, while not the largest, are rapidly gaining traction as they play a significant role in confirming the effectiveness of new therapeutics, which is increasingly important to stakeholders. Growth trends indicate that the demand for Safety Biomarkers remains robust, driven by regulatory emphasis on patient safety and the rise in clinical trial activities. Conversely, Efficacy Biomarkers are experiencing the fastest growth as pharmaceutical companies prioritize developing drugs that not only are safe but also demonstrate clear evidence of efficacy, prompting innovations and investments in this area.

Safety Biomarker (Dominant) vs. Efficacy Biomarker (Emerging)

Safety Biomarkers exhibit dominance in the market due to their foundational role in clinical trials, ensuring that drug developments do not compromise patient safety. They are essential for identifying potential adverse effects early in the testing phase. Efficacy Biomarkers are emerging as crucial tools that are increasingly integrated into drug development processes, helping to establish the therapeutic effectiveness of new treatments. The combination of both types serves as a comprehensive framework for drug development, with Safety Biomarkers setting the groundwork while Efficacy Biomarkers drive forward the validation of new therapies.

### By Application: Drug Discovery & Development (Largest) vs. Personalized Medicine (Fastest-Growing)

In the US central nervous-system-biomarkers market, the Drug Discovery & Development segment holds a dominant market share. It significantly influences innovation and research, driving the overall market with its established presence and robust application in various therapeutic areas. On the other hand, Personalized Medicine is rapidly gaining traction, reflecting a shift towards tailored treatments, thereby attracting attention from both researchers and healthcare providers. This segment, while smaller in market share, is poised for substantial growth as advancements in biomarkers and genomics unfold. The growth trends within these segments are primarily driven by technological advancements and increasing demand for targeted therapies. Drug Discovery & Development benefits from ongoing investments and collaborations aimed at streamlining drug pipelines. Meanwhile, Personalized Medicine is fueled by the rising prevalence of neurological disorders and an increased emphasis on precision medicine approaches which enhance treatment efficacy. This dual focus on innovation and patient-centered care is shaping the future growth landscape in the US central nervous-system-biomarkers market.

Drug Discovery & Development (Dominant) vs. [Personalized Medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) (Emerging)

The Drug Discovery & Development segment stands as the dominant force within the US central nervous-system-biomarkers market, characterized by extensive research activities and significant funding. This segment encompasses the identification and validation of biomarkers that are crucial for therapeutic development. Its established framework allows for accelerated drug approvals and effective treatment strategies. Conversely, the Personalized Medicine segment is emerging robustly, motivated by the need for individualized treatment plans that cater specifically to a patient's genetic makeup and disease profile. This shift towards personalized approaches is fostering innovative solutions in treatment methodologies, emphasizing the importance of biomarkers in designing specific therapies that enhance patient outcomes. As the landscape evolves, both segments play critical roles in advancing the market.

### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Labs (Fastest-Growing)

In the US central nervous-system-biomarkers market, the distribution of market share among the end-user segments reveals that Hospitals & Clinics hold the largest share due to their comprehensive infrastructure and patient access. Diagnostic Labs are also significant players, though their share is smaller compared to the former. Research Centers, while crucial for innovation, occupy a niche segment in this market, leading to their comparatively lower share.

End Users: Hospitals & Clinics (Dominant) vs. Research Centers (Emerging)

Hospitals & Clinics dominate the US central nervous-system-biomarkers market due to their extensive patient interaction and the capability to conduct various diagnostic procedures on-site. Their established networks enable efficient data collection and patient follow-up, ultimately leading to better patient outcomes. In contrast, Research Centers are emerging as vital contributors through their focus on innovative biomarker research and development. While they may not have the same immediate impact on market share, their role in advancing scientific knowledge and methodologies positions them as significant influencers in future market dynamics.

## Competitive Benchmarking

The central nervous-system-biomarkers market is characterized by a dynamic competitive landscape, driven by advancements in diagnostic technologies and an increasing prevalence of neurological disorders. Key players such as Roche (CH), AbbVie (US), and Biogen (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Roche (CH) focuses on integrating cutting-edge biomarker research with its existing diagnostic portfolio, while AbbVie (US) emphasizes collaborations with academic institutions to foster innovation in biomarker discovery. Biogen (US) is actively pursuing digital transformation initiatives to streamline its operations and improve patient outcomes, collectively shaping a competitive environment that prioritizes innovation and strategic alliances. The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce costs and enhance responsiveness to market demands. This strategy not only improves supply chain efficiency but also allows for better compliance with regional regulations, thereby strengthening their competitive positioning. The collective influence of these key players is significant, as they drive market trends and set benchmarks for quality and innovation. In October 2025, Roche (CH) announced a partnership with a leading AI firm to develop predictive analytics tools for early diagnosis of neurodegenerative diseases. This strategic move is likely to enhance Roche's capabilities in biomarker identification and patient stratification, positioning the company at the forefront of personalized medicine. The integration of AI into their diagnostic processes could potentially revolutionize how neurological disorders are diagnosed and treated, thereby expanding Roche's market share. In September 2025, AbbVie (US) launched a new biomarker-driven clinical trial aimed at assessing the efficacy of its latest therapeutic candidate for Alzheimer's disease. This initiative underscores AbbVie's commitment to advancing precision medicine and highlights the importance of biomarkers in clinical research. By focusing on biomarker validation, AbbVie is not only enhancing its product pipeline but also reinforcing its reputation as a leader in neurological therapeutics. In August 2025, Biogen (US) unveiled a digital health platform designed to monitor patients with multiple sclerosis through real-time biomarker tracking. This innovative approach reflects Biogen's strategic focus on integrating technology with healthcare solutions, potentially improving patient engagement and treatment adherence. The platform's success could serve as a model for future digital health initiatives within the central nervous-system-biomarkers market. As of November 2025, current trends indicate a shift towards digitalization, sustainability, and AI integration within the competitive landscape. Strategic alliances are increasingly shaping the market, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, innovative solutions, and reliable supply chains. This transition may redefine how companies compete, emphasizing the importance of agility and responsiveness in a rapidly changing market.

## Recent News & Developments

In recent months, the US Central Nervous System Biomarkers Market has seen notable advancements and developments, particularly concerning key players like Teva Pharmaceutical Industries, AstraZeneca, and Eli Lilly. In September 2023, Teva announced a strategic partnership with a biotechnology firm to develop new neurological biomarkers which could enhance the diagnosis and management of neurological disorders.

Additionally, AstraZeneca's recent focus on neurodegenerative diseases has led to promising results in clinical trials for biomarkers that could potentially improve treatment outcomes. Furthermore, in October 2023, Eli Lilly reported positive progress with its Alzheimer’s disease biomarker, showing potential for earlier diagnosis, thus impacting market dynamics favorably.

In terms of mergers and acquisitions, in July 2023, Merck acquired a startup specialized in CNS biomarker technologies, a move expected to strengthen its research capabilities in neurodegenerative diseases. The valuation of companies within this market has been significant due to increased investments directed at Research and Development, driven by the rise in neurological disorders in the US. Over the past two years, there has been a growing emphasis on precision medicine within the CNS biomarkers landscape, marking an evolution in how neurological diseases are approached and managed in clinical settings.

## Report Scope

| MARKET SIZE 2024 | 1823.3(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1975.55(USD Million) |
| MARKET SIZE 2035 | 4405.24(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.35% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (CH), AbbVie (US), Biogen (US), Eli Lilly (US), Novartis (CH), Amgen (US), Merck (DE), Pfizer (US), Johnson & Johnson (US) |
| Segments Covered | Type, Application, End User |
| Key Market Opportunities | Advancements in neuroimaging technologies enhance diagnostic capabilities in the central nervous-system-biomarkers market. |
| Key Market Dynamics | Rising demand for innovative diagnostics drives competition and regulatory scrutiny in the central nervous system biomarkers market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US central nervous-system-biomarkers market in 2024?**
A: The market valuation was $1823.3 Million in 2024.

**Q: What is the projected market valuation for the US central nervous-system-biomarkers market by 2035?**
A: The projected valuation for 2035 is $4405.24 Million.

**Q: What is the expected CAGR for the US central nervous-system-biomarkers market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 8.35%.

**Q: Which companies are considered key players in the US central nervous-system-biomarkers market?**
A: Key players include Roche, AbbVie, Biogen, Eli Lilly, Novartis, Amgen, Merck, Pfizer, and Johnson & Johnson.

**Q: What are the main segments of the US central nervous-system-biomarkers market?**
A: The main segments include Type, Application, and End User.

**Q: What was the valuation range for Safety Biomarkers in the US central nervous-system-biomarkers market?**
A: The valuation range for Safety Biomarkers was $364.66 Million to $880.0 Million.

**Q: How much is the Drug Discovery & Development application segment valued in the US central nervous-system-biomarkers market?**
A: The Drug Discovery & Development segment is valued between $800.0 Million and $2000.0 Million.

**Q: What is the valuation range for Hospitals & Clinics as an end user in the US central nervous-system-biomarkers market?**
A: The valuation range for Hospitals & Clinics is $1093.98 Million to $2600.0 Million.

**Q: What is the projected growth trend for Efficacy Biomarkers in the US central nervous-system-biomarkers market?**
A: Efficacy Biomarkers are projected to grow from $546.99 Million to $1300.0 Million.

**Q: What does the future hold for the US central nervous-system-biomarkers market in terms of innovation?**
A: The market is likely to see increased innovation driven by key players and advancements in personalized medicine.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-central-nervous-system-biomarkers-market-19327*